Apogee Therapeutics, Inc. Stock-Based Compensation
Apogee Therapeutics, Inc. (APGE) reported Stock-Based Compensation of $33.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-10
- Apogee Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $16.66M, a 46.89% increase year-over-year.
- Apogee Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $17.16M, a 54.19% increase year-over-year.
- Apogee Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $11.93M, a 56.79% increase year-over-year.
- Apogee Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $11.88M, a 103.41% increase year-over-year.
- Apogee Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $46.28M, a 98.34% increase from fiscal 2024.
- Apogee Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $23.33M, a 282.30% increase from fiscal 2023.
- Apogee Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $6.10M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 5 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 11 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $16.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $33.82M 10-Q · filed 2026-08-10 | $45.75M derived: sum of 3 quarters · filed 2026-08-10 | $57.63M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $17.16M 10-Q · filed 2026-05-11 | $29.09M derived: sum of 2 quarters · filed 2026-05-11 | $40.96M derived: sum of 3 quarters · filed 2026-05-11 | $52.31M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | $11.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $23.81M derived: sum of 2 quarters · filed 2026-03-02 | $35.15M derived: sum of 3 quarters · filed 2026-08-10 | $46.28M 10-K · filed 2026-03-02 | ||
| 2025-09-30 | $11.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $23.22M derived: sum of 2 quarters · filed 2026-08-10 | $34.35M 10-Q · filed 2025-11-10 | $41.96M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | $11.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $22.47M 10-Q · filed 2026-08-10 | $30.08M derived: sum of 3 quarters · filed 2026-08-10 | $35.92M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $11.13M 10-Q · filed 2026-05-11 | $18.73M derived: sum of 2 quarters · filed 2026-05-11 | $24.57M derived: sum of 3 quarters · filed 2026-05-11 | $30.27M derived: sum of 4 quarters · filed 2026-05-11 | ||
| 2024-12-31 | $7.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $13.45M derived: sum of 2 quarters · filed 2026-03-02 | $19.15M derived: sum of 3 quarters · filed 2026-03-02 | $23.33M 10-K · filed 2026-03-02 | ||
| 2024-09-30 | $5.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $11.54M derived: sum of 2 quarters · filed 2025-11-10 | $15.72M 10-Q · filed 2025-11-10 | $17.93M derived: sum of 4 quarters · filed 2026-03-02 | ||
| 2024-06-30 | $5.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $9.88M 10-Q · filed 2025-08-11 | $12.10M derived: sum of 3 quarters · filed 2026-03-02 | $13.60M derived: sum of 4 quarters · filed 2026-03-02 | ||
| 2024-03-31 | $4.19M 10-Q · filed 2025-05-12 | $6.40M derived: sum of 2 quarters · filed 2026-03-02 | $7.90M derived: sum of 3 quarters · filed 2026-03-02 | $9.02M derived: sum of 4 quarters · filed 2026-03-02 | ||
| 2023-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $3.72M derived: sum of 2 quarters · filed 2026-03-02 | $4.83M derived: sum of 3 quarters · filed 2026-03-02 | $6.10M 10-K · filed 2026-03-02 | ||
| 2023-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.62M derived: sum of 2 quarters · filed 2024-11-12 | $3.89M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | $1.11M 10-Q · filed 2023-08-28 | $2.39M 10-Q · filed 2024-08-12 | ||||
| 2023-03-31 | $1.27M 10-Q · filed 2024-05-13 | |||||
| 2022-12-31 | $2.14M 10-K · filed 2024-03-05 | |||||
| 2022-06-30 | $1.70M 10-Q · filed 2023-08-28 |